

For Immediate Release

Troy, New York

March 4, 2009

Solidus Biosciences announced that David Rozzell, Ph.D., has accepted the position of President and CEO of the company. “Solidus Biosciences is delighted to have David join Solidus as CEO. His experience both in developing technology and running a biotechnology company are an excellent match for Solidus, and he will lead the next phase of growth at the company,” said Company co-founder Jonathan Dordick, Howard P. Isermann Professor of Chemical and Biological of Engineering at Rensselaer Polytechnic Institute.

Dr. Rozzell has more than 25 years of experience working in the biotechnology industry, both as a scientist and executive. He has done extensive work in the fields of biocatalysis and enzyme technology, including the development and launch of the first Human Cytochrome Biocatalyst product line for drug metabolite synthesis. Previously, he was the Founder and CEO of BioCatalytics, Inc., a leading developer of enzymes and related technology for chemical synthesis, and joined Codexis, Inc. in 2007 as VP, Biocatalysis Technology and Applications following the acquisition of BioCatalytics, Inc. by Codexis. Dr. Rozzell has authored numerous scientific articles, spoken widely at international symposia, and is the inventor on more than 20 issued US patents. He received a PhD in Chemistry from Harvard University and a BS in Chemistry from the University of Virginia.

Contact David Rozzell, Solidus Biosciences

[Rozzell@solidusbio.com](mailto:Rozzell@solidusbio.com)

Tel: 818-388-6576

###